

MD 20857, 301-827-7001, FAX: 301-827-6776 or e-mail: [patelA@cder.fda.gov](mailto:patelA@cder.fda.gov), or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area) code 3014512544. Please call the Information Line for up to date information on this meeting.

**Agenda:** The Psychopharmacologic Drugs Advisory Committee and the Pediatric Subcommittee of the Anti-Infective Drugs Advisory Committee will discuss reports of the occurrence of suicidality (both suicidal ideation and suicide attempts) in clinical trials for various anti-depressant drugs in pediatric patients with major depressive disorder (MDD). The committee will consider optimal approaches to the analysis of data from these trials as well as further research needs to address these issues. The committee will not be considering options for definitive regulatory action at this meeting because definitive analyses of the data have not been completed. This topic will be covered in a second meeting to be scheduled by summer 2004.

**Procedure:** Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by January 26, 2004. Oral presentations from the public will be scheduled between approximately 9:30 a.m. to 11:30 a.m., and 2 p.m. to 2:30 p.m.

This notice is given under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

Dated: January 5, 2004.

**Peter J. Pitts,**

*Associate Commissioner for External Relations.*

[FR Doc. 04-502 Filed 1-9-04; 8:45 am]

BILLING CODE 4160-01-S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Center for Research Resources; Notice of Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. appendix 2), notice is hereby given of the following meetings.

The meetings will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other

reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** Scientific and Technical Review Board on Biomedical and Behavioral Research Facilities.

**Date:** February 23-25, 2004.

**Open:** February 23, 2004, 8 a.m. to 9 a.m.

**Agenda:** To discuss planning and other issues.

**Place:** Gaithersburg Marriott, Washingtonian Center, 9751 Washingtonian Blvd., Gaithersburg, MD 20878.

**Closed:** February 23, 2004, 9 a.m. to Adjournment.

**Agenda:** To review and evaluate grant applications.

**Place:** Gaithersburg Marriott, Washingtonian Center, 9751 Washingtonian Blvd., Gaithersburg, MD 20878.

**Contact Person:** D.G. Patel, PhD, Scientific Review Administrator, National Institutes of Health, National Center for Research Resources, Office of Review, 6701 Democracy Boulevard, 1 Democracy Plaza, Room 1070, Bethesda, MD 20892, 301-435-0824, [pateldg@mail.nih.gov](mailto:pateldg@mail.nih.gov).

**Name of Committee:** National Center for Research Resources Special Emphasis Panel, Research Infrastructure.

**Date:** February 25-26, 2004.

**Time:** February 25, 2004, 8 a.m. to Adjournment.

**Agenda:** To review and evaluate grant applications.

**Place:** Marriott Gaithersburg, Washingtonian Center, 9751 Washingtonian Boulevard, Gaithersburg, MD 20878.

**Contact Person:** Eric H. Brown, PhD, Scientific Review Administrator, Office of Review, National Center for Research Resources, National Institutes of Health, 6701 Democracy Blvd, MSC 4874, Room 1068, Bethesda, MD 20892-4874, 301-435-0815, [browne@mail.nih.gov](mailto:browne@mail.nih.gov).

**Name of Committee:** National Center for Research Resources Special Emphasis Panel, Research Infrastructure.

**Date:** March 10-11, 2004.

**Time:** March 10, 2004, 8 a.m. to Adjournment.

**Agenda:** To review and evaluate grant applications.

**Place:** Marriott Gaithersburg, Washingtonian Center, 9751 Washingtonian Boulevard, Gaithersburg, MD 20878.

**Contact Person:** Eric H. Brown, PhD, Scientific Review Administrator, Office of Review, National Center for Research Resources, National Institutes of Health, 6701 Democracy Blvd, MSC 4874, Room 1068,

Bethesda, MD 20892, 301-435-0815, [browne@mail.nih.gov](mailto:browne@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research; 93.371, Biomedical Technology; 93.389, Research Infrastructure; 93.306, 93.333, National Institutes of Health, HHS)

Dated: January 6, 2004.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 04-578 Filed 1-9-04; 8:45 am]

BILLING CODE 4140-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of Allergy and Infectious Diseases Special Emphasis Panel, Unsolicited P01.

**Date:** January 21, 2004.

**Time:** 9 a.m. to 12 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, Rockledge 6700, 6700B Rockledge Drive, Bethesda, MD 20817 (Telephone Conference Call).

**Contact Person:** Cheryl K. Lapham, PhD, Scientific Review Administrator, Scientific Review Program, National Institute of Allergy and Infectious Diseases, DEA/NIH/DHHS, 6700-B Rockledge Drive, MSC 7616, Room 3127, Bethesda, MD 20892-7616, 301-402-4598, [clapham@niaid.nih.gov](mailto:clapham@niaid.nih.gov).

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

**Name of Committee:** National Institute of Allergy and Infectious Diseases Special Emphasis Panel, Unsolicited Program Project Application.

**Date:** February 4, 2004.

**Time:** 9 a.m. to 1 p.m.